CASTLE BIOSCIENCES, INC. Revenue
CASTLE BIOSCIENCES, INC. (CSTL) reported Revenue of $103.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-30
- CASTLE BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $103.55M, a 20.14% increase year-over-year.
- CASTLE BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $83.68M, a 4.90% decline year-over-year.
- CASTLE BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $87.01M, a 0.81% increase year-over-year.
- CASTLE BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $83.04M, a 3.19% decline year-over-year.
- CASTLE BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $344.23M, a 3.66% increase from fiscal 2024.
- CASTLE BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $332.07M, a 51.09% increase from fiscal 2023.
- CASTLE BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $219.79M, a 60.38% increase from fiscal 2022.
- CASTLE BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $137.04M, a 45.65% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $103.55M 10-Q · filed 2026-07-30 | $187.22M 10-Q · filed 2026-07-30 | $274.24M derived: sum of 3 quarters · filed 2026-07-30 | $357.28M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $83.68M 10-Q · filed 2026-05-06 | $170.69M derived: sum of 2 quarters · filed 2026-05-06 | $253.73M derived: sum of 3 quarters · filed 2026-05-06 | $339.92M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-12-31 | $87.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $170.05M derived: sum of 2 quarters · filed 2026-02-26 | $256.24M derived: sum of 3 quarters · filed 2026-07-30 | $344.23M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $83.04M 10-Q · filed 2025-11-03 | $169.23M derived: sum of 2 quarters · filed 2026-07-30 | $257.22M 10-Q · filed 2025-11-03 | $343.53M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-06-30 | $86.19M 10-Q · filed 2026-07-30 | $174.18M 10-Q · filed 2026-07-30 | $260.49M derived: sum of 3 quarters · filed 2026-07-30 | $346.27M derived: sum of 4 quarters · filed 2026-07-30 | |||
| 2025-03-31 | $87.99M 10-Q · filed 2026-05-06 | $174.30M derived: sum of 2 quarters · filed 2026-05-06 | $260.08M derived: sum of 3 quarters · filed 2026-05-06 | $347.08M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $86.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $172.09M derived: sum of 2 quarters · filed 2026-02-26 | $259.10M derived: sum of 3 quarters · filed 2026-02-26 | $332.07M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $85.78M 10-Q · filed 2025-11-03 | $172.78M derived: sum of 2 quarters · filed 2025-11-03 | $245.76M 10-Q · filed 2025-11-03 | $311.88M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $87.00M 10-Q · filed 2025-08-04 | $159.98M 10-Q · filed 2025-08-04 | $226.10M derived: sum of 3 quarters · filed 2026-02-26 | $287.59M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $72.97M 10-Q · filed 2025-05-05 | $139.09M derived: sum of 2 quarters · filed 2026-02-26 | $200.59M derived: sum of 3 quarters · filed 2026-02-26 | $250.72M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $66.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $127.61M derived: sum of 2 quarters · filed 2026-02-26 | $177.75M derived: sum of 3 quarters · filed 2026-02-26 | $219.79M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $61.49M 10-Q · filed 2024-11-04 | $111.63M derived: sum of 2 quarters · filed 2024-11-04 | $153.67M 10-Q · filed 2024-11-04 | $192.01M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $50.14M 10-Q · filed 2024-08-05 | $92.17M 10-Q · filed 2024-08-05 | $130.51M derived: sum of 3 quarters · filed 2025-02-27 | $167.52M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $42.04M 10-Q · filed 2024-05-02 | $80.38M derived: sum of 2 quarters · filed 2025-02-27 | $117.39M derived: sum of 3 quarters · filed 2025-02-27 | $152.22M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $38.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $75.35M derived: sum of 2 quarters · filed 2025-02-27 | $110.19M derived: sum of 3 quarters · filed 2025-02-27 | $137.04M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $37.01M 10-Q · filed 2023-11-02 | $71.85M derived: sum of 2 quarters · filed 2023-11-02 | $98.70M 10-Q · filed 2023-11-02 | $123.74M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $34.84M 10-Q · filed 2023-08-02 | $61.69M 10-Q · filed 2023-08-02 | $86.73M derived: sum of 3 quarters · filed 2023-08-02 | $110.20M derived: sum of 4 quarters · filed 2023-08-02 | |||
| 2022-03-31 | $26.85M 10-Q · filed 2023-05-03 | $51.89M derived: sum of 2 quarters · filed 2023-05-03 | $75.37M derived: sum of 3 quarters · filed 2023-05-03 | $98.12M derived: sum of 4 quarters · filed 2023-05-03 | |||
| 2021-12-31 | $25.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $48.51M derived: sum of 2 quarters · filed 2023-02-28 | $71.27M derived: sum of 3 quarters · filed 2023-02-28 | $94.08M 10-K · filed 2023-02-28 | |||
| 2021-09-30 | $23.48M 10-Q · filed 2022-11-02 | $46.23M derived: sum of 2 quarters · filed 2022-11-02 | $69.05M 10-Q · filed 2022-11-02 | $86.34M derived: sum of 4 quarters · filed 2022-11-02 | |||
| 2021-06-30 | $22.76M 10-Q · filed 2022-08-08 | $45.57M 10-Q · filed 2022-08-08 | $62.87M derived: sum of 3 quarters · filed 2022-08-08 | $78.09M derived: sum of 4 quarters · filed 2022-08-08 | |||
| 2021-03-31 | $22.81M 10-Q · filed 2022-05-09 | $40.11M derived: sum of 2 quarters · filed 2022-05-09 | $55.33M derived: sum of 3 quarters · filed 2022-05-09 | $68.04M derived: sum of 4 quarters · filed 2022-05-09 | |||
| 2020-12-31 | $17.30M 10-K · filed 2021-03-11 | $32.52M derived: sum of 2 quarters · filed 2021-11-08 | $45.23M derived: sum of 3 quarters · filed 2021-11-08 | $62.65M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $15.22M 10-Q · filed 2021-11-08 | $27.93M derived: sum of 2 quarters · filed 2021-11-08 | $45.35M 10-Q · filed 2021-11-08 | $62.98M derived: sum of 4 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $12.71M 10-Q · filed 2021-08-09 | $30.13M 10-Q · filed 2021-08-09 | $47.77M derived: sum of 3 quarters · filed 2021-08-09 | $62.54M derived: sum of 4 quarters · filed 2021-08-09 | |||
| 2020-03-31 | $17.42M 10-Q · filed 2021-05-10 | $35.05M derived: sum of 2 quarters · filed 2021-05-10 | $49.83M derived: sum of 3 quarters · filed 2021-05-10 | $60.57M derived: sum of 4 quarters · filed 2021-05-10 | |||
| 2019-12-31 | $17.64M 10-K · filed 2021-03-11 | $32.41M derived: sum of 2 quarters · filed 2021-03-11 | $43.15M derived: sum of 3 quarters · filed 2021-03-11 | $51.87M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $14.77M 10-K · filed 2021-03-11 | $14.77M 10-Q · filed 2019-11-12 | $25.51M derived: sum of 2 quarters · filed 2021-03-11 | $34.23M 10-Q · filed 2020-11-09 | $34.23M 10-Q · filed 2019-11-12 | $45.67M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2019-06-30 | $10.74M 10-K · filed 2021-03-11 | $10.74M 10-Q · filed 2019-09-03 | $19.46M 10-Q · filed 2020-08-10 | $19.46M 10-Q · filed 2019-09-03 | $30.89M derived: sum of 3 quarters · filed 2021-03-11 | $34.60M derived: sum of 4 quarters · filed 2021-03-11 | |
| 2019-03-31 | $8.72M 10-K · filed 2021-03-11 | $20.15M derived: sum of 2 quarters · filed 2021-03-11 | $23.86M derived: sum of 3 quarters · filed 2021-03-11 | $27.84M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-12-31 | $11.44M 10-K · filed 2020-03-10 | $15.15M derived: sum of 2 quarters · filed 2020-03-10 | $19.13M derived: sum of 3 quarters · filed 2020-03-10 | $22.79M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | $3.71M 10-K · filed 2020-03-10 | $3.71M 10-Q · filed 2019-11-12 | $7.69M derived: sum of 2 quarters · filed 2020-03-10 | $11.35M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $3.98M 10-K · filed 2020-03-10 | $3.98M 10-Q · filed 2019-09-03 | $7.64M 10-Q · filed 2019-09-03 | ||||
| 2018-03-31 | $3.66M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |